temozolomide has been researched along with Headache in 11 studies
Headache: The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.
Excerpt | Relevance | Reference |
---|---|---|
"Temozolomide (200 mg/m2 oral administration) was given to 12 patients with metastatic malignant melanoma." | 9.11 | Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. ( Boddy, AV; Calvert, AH; Curtin, NJ; Harris, AL; Hickson, I; Jones, C; Margison, GP; McGown, G; McHugh, P; Middleton, MR; Newell, DR; Olsen, A; Plummer, ER; Thorncroft, M; Watson, AJ, 2005) |
"Temozolomide (200 mg/m2 oral administration) was given to 12 patients with metastatic malignant melanoma." | 5.11 | Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. ( Boddy, AV; Calvert, AH; Curtin, NJ; Harris, AL; Hickson, I; Jones, C; Margison, GP; McGown, G; McHugh, P; Middleton, MR; Newell, DR; Olsen, A; Plummer, ER; Thorncroft, M; Watson, AJ, 2005) |
" The observed adverse effects of temozolomide included nausea, vomiting, headache, constipation, mild marrow suppression, and decreased activity; none of them was severe enough to discontinue the treatment." | 3.75 | Efficacy of temozolomide for recurrent embryonal brain tumors in children. ( Chang, KP; Hsu, TR; Wang, CH; Wong, TT, 2009) |
"Ratio of log-transformed means (intravenous:oral) of area under the concentration-time curve and maximum concentration of drug after dosing for temozolomide and 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC) met exposure equivalence criteria (90% confidence interval = 0." | 2.75 | Evaluation of the exposure equivalence of oral versus intravenous temozolomide. ( Abutarif, MA; Cantillon, M; Cutler, D; Diez, BD; Kantesaria, B; Ottaviano, FH; Pallotta, MG; Schwarz, M; Statkevich, P; Xuan, F; Zhu, Y, 2010) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (45.45) | 29.6817 |
2010's | 4 (36.36) | 24.3611 |
2020's | 2 (18.18) | 2.80 |
Authors | Studies |
---|---|
Li, F | 1 |
Zhang, Y | 1 |
Wang, N | 1 |
Song, C | 1 |
Gao, Y | 1 |
Diao, X | 1 |
Zhang, H | 1 |
Sarper, B | 1 |
Yaprak Bayrak, B | 1 |
Halis, H | 1 |
Alparslan, B | 1 |
Yeni Bayraktar, H | 1 |
Bilbao, I | 1 |
Egaña, N | 1 |
García, C | 1 |
Olaizola, I | 1 |
Yeo, KK | 1 |
Puscasiu, E | 1 |
Keating, RF | 1 |
Rood, BR | 1 |
Zakaria, Z | 1 |
Fenton, E | 1 |
Khalil, A | 1 |
Sattar, MT | 1 |
Molnar, P | 1 |
Wang, CH | 1 |
Hsu, TR | 1 |
Wong, TT | 1 |
Chang, KP | 1 |
Diez, BD | 1 |
Statkevich, P | 1 |
Zhu, Y | 1 |
Abutarif, MA | 1 |
Xuan, F | 1 |
Kantesaria, B | 1 |
Cutler, D | 1 |
Cantillon, M | 1 |
Schwarz, M | 1 |
Pallotta, MG | 1 |
Ottaviano, FH | 1 |
Rojas-Marcos, I | 1 |
Calvet, D | 1 |
Janoray, P | 1 |
Delattre, JY | 1 |
Harkness, KA | 1 |
Manford, MR | 1 |
Plummer, ER | 1 |
Middleton, MR | 1 |
Jones, C | 1 |
Olsen, A | 1 |
Hickson, I | 1 |
McHugh, P | 1 |
Margison, GP | 1 |
McGown, G | 1 |
Thorncroft, M | 1 |
Watson, AJ | 1 |
Boddy, AV | 1 |
Calvert, AH | 1 |
Harris, AL | 1 |
Newell, DR | 1 |
Curtin, NJ | 1 |
Steckley, JL | 1 |
Watling, CJ | 1 |
Ng, W | 1 |
2 trials available for temozolomide and Headache
Article | Year |
---|---|
Evaluation of the exposure equivalence of oral versus intravenous temozolomide.
Topics: Administration, Oral; Adult; Anemia; Antineoplastic Agents, Alkylating; Area Under Curve; Central Ne | 2010 |
Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Comet Assay; Dacarbazine; DNA Dam | 2005 |
9 other studies available for temozolomide and Headache
Article | Year |
---|---|
Evaluation of the Prognosis of Neuroglioma Based on Dynamic Magnetic Resonance Enhancement.
Topics: Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Chemotherapy, Adjuvant; Contrast Me | 2020 |
Malignant Astroblastoma
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Bevacizumab; Headache; Huma | 2020 |
Failure of a second temozolomide cycle in a patient with a prolactin-secreting pituitary carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bromocriptine; Cabergoline; Combined | 2017 |
Durable response of intracranial cellular hemangioma to bevacizumab and temozolomide.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2013 |
Stupp-treated glioblastoma accompanied by EBV-positive primary CNS lymphoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Protocols; Dac | 2014 |
Efficacy of temozolomide for recurrent embryonal brain tumors in children.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; D | 2009 |
Response of recurrent anaplastic ependymoma to a combination of tamoxifen and isotretinoin.
Topics: Adrenal Cortex Hormones; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplas | 2003 |
Metastatic malignant melanoma presenting as a cavernous sinus syndrome.
Topics: Adult; Antineoplastic Agents; Biomarkers, Tumor; Blepharoptosis; Cavernous Sinus Thrombosis; Cranial | 2004 |
Glioblastoma in a patient with a hereditary cancer syndrome.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Hemorrhage; Colorectal Neoplasms; | 2008 |